Livzon Pharmaceutical Group Inc. is a pharmaceutical company engaged in the research, development, production, and marketing of chemical drugs, biological products, traditional Chinese medicine preparations, active pharmaceutical ingredients (APIs), and diagnostic reagents. The company's product portfolio focuses on therapeutic areas including gastroenterology, neuropsychiatry, and gonadotropin-releasing hormone (GnRH) agonists for assisted reproduction and oncology. Key products include Leuprorelin Microspheres, Triptorelin Acetate Microspheres, and the IL-17A/F inhibitor Lecankitug. The company also manufactures APIs and intermediates and offers diagnostic reagents and equipment. Livzon serves markets in China and internationally, with a strategic focus on internationalization and global innovation. The company is a subsidiary of Joincare Pharmaceutical Industry Group Co., Ltd. and operates through subsidiaries such as Livzon MABPharm, Zhuhai Livzon Diagnostics, and Sichuan Guangda Pharmaceutical.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Drug Manufacturers - General Homepage livzon.com.cn
Sector Healthcare IR page livzon.com.cn/Investor
Tags
chemical drugs, biological products, traditional chinese medicine, active pharmaceutical ingredients, diagnostic reagents, gastroenterology, neuropsychiatry, gonadotropin-releasing hormone, assisted reproduction, oncology, vaccines, antibiotics, Leuprorelin Microspheres for Injection, Triptorelin Acetate Microspheres for Injection, Lecankitug Injection, Ilaprazole Enteric-Coated Tablets, Ilaprazole Sodium for Injection, Aripiprazole Microspheres for Injection, Brexpiprazole Microspheres, Semaglutide Injection, Tocilizumab, Livzon MABPharm, Zhuhai Livzon Diagnostics, Sichuan Guangda Pharmaceutical, Joincare Pharmaceutical Industry Group, Livzon Hecheng, Jiaozuo Hecheng, Xinbeijiang Pharma, Fuzhou Fuxing, Ningxia Pharma, Livzon Pharmaceutical Factory, Shanghai Livzon, Jiaozuo Joincare, Haibin Pharma, Lanbao Pharma, Sanmed Gene, Livzon Hong Kong, Shengmei Bio, Livzon Cayman, Livzon HK, Livzon Bio, Begol
Press page livzon.com.cn/news_list

Metrics

Valuation  
Market cap HK$ 7.39B
Market cap (USD) $ 941.793M
P/E 9.67
PEG —
P/BV —
P/S 0.71
P/OCF 4.95
P/FCF —
Dividend yield 17.3%
Turnover / mcap 0.50%
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) -21.6%
Quality  
Profitable Yes
Margin expanding No
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 30.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Revenue — — — — — — — 8.861B 8.531B 7.652B 6.621B 5.544B 4.619B 3.944B
Net profit — — — — — 2.131B — 1.082B 4.429B 784.354M 622.641M 515.978M 487.502M 441.672M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012
Share price — — — — — — 24.56 23.6 — — — — — —
Price performance 12m — — — — — — 0.01 — — — — — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Livzon Pharmaceutical Group Inc. (ticker 1513), listed in Hong Kong.

ETFs Holding Livzon Pharmaceutical Group Inc.

ETF Weight in ETF Shares Market value As of
DFEM 0.01% 207,700 $ 651.325K Nov 12, 2026
DFAE 0.00% 103,500 $ 324.565K Nov 12, 2026
DFAX 0.00% 121,156 $ 379.933K Nov 12, 2026